Discover the fundamentals of antibodies with our informative blogs. Learn about their structure, function, and role in the immune system.
Similar binding, different development risks: learn how early stability, self-interaction, and polyspecificity data help prioritize antibody candidates.
When should you move beyond supernatant screening? Learn when purified binding analysis and developability profiling can inform antibody lead selection.
For an antibody candidate, strong target binding is only part of the path toward a successful therapeutic. A molecule can show high affinity and selectivity yet encounter problems later because of poor stability, low expression, aggregation, non-specific binding, or other unfavorable biophysical properties.
Clinical drug development remains associated with a high failure rate, primarily to lack of efficacy, unmanageable toxicity, and suboptimal drug-like properties. These data indicate that, despite extensive optimization workflows, current strategies do not fully capture all determinants of clinical success.
Learn how monoclonal antibodies benefit from screening in development, covering biophysical properties, thermal stability, and machine learning drug discovery.
Learn what makes an antibody developable, including stability, aggregation, manufacturability, formulation, and in silico prediction methods.
Learn why early antibody developability assessment is critical for lead selection, manufacturability, stability, and reducing risk in antibody drug development.
Explore how machine learning improves antibody developability, screening, and optimization by predicting biophysical properties and enhancing drug discovery outcomes.
Explore how computational predictors like SCM, TAP, and AlphaFold support therapeutic antibody development through AI-driven workflows and in silico tools.